Ro
Ro is a direct-to-patient healthcare company offering telehealth, lab, and pharmacy services through its vertically integrated platform.
Secondary Market Price
How Ro Measures Up
To help you manage your Ro equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series D
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Ro's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Ro Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Ro's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Ro is a direct-to-patient healthcare company that provides telehealth, in-home care, diagnostics, and pharmacy services. Founded in 2017 by Zachariah Reitano, Saman Rahmanian, and Rob Schutz, the company initially focused on treatments for erectile dysfunction and smoking cessation. It has since expanded its offerings, operating a platform that handles processes from diagnosis to medication delivery. Ro's services now include access to GLP-1 medications, and it also provides business-to-business solutions like Workpath, an in-home care API, and Kit, an at-home diagnostic testing service for other healthcare companies. The company has raised a total of $876.3 million in funding.
Recent company developments point toward a focus on obesity care, technology integration, and clinical research. Ro launched nationwide access to the Wegovy pill and introduced a new feature to give patients more transparency into the insurance prior authorization process. The company also deployed an LLM-powered tool that it reports has reduced median response times for patient messages about side effects by 71%. In addition, Ro has published peer-reviewed research in The Obesity Society’s journal, with one study showing patients on its platform lost an average of 16.6% of their body weight over 68 weeks. The company also plans to present eight research abstracts at the upcoming ObesityWeek 2025 conference.
- General Catalyst
- FirstMark Capital
- TQ Ventures
- SignalFire
- Torch Capital
- BoxGroup
- Altimeter Capital
- Baupost Group
- Dragoneer Investment Group
- ShawSpring Partners
- Radcliff
- Seven Seven Six
- The Chernin Group
- Initialized Capital
- 3L
- Leonis Capital
- Co-Founder, Zachariah Reitano
- Co-Founder, Saman Rahmanian
- Co-Founder, Rob Schutz
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Ro worth joining?
Deciding to join any company depends on various personal and professional factors, including the potential value of its equity compensation. Tools like Prospect can help you model the future value of your equity to make a more informed decision.
What should I do with my Ro stock?
Managing private company stock involves complex decisions about when to exercise options and how to plan for taxes. Using a platform like Prospect can help you create an optimized strategy to maximize your post-tax equity value.
Can you sell Ro stock?
As Ro is a private company, selling stock is typically possible only during specific events like tender offers or on secondary markets. Prospect offers tools to help you decide how much to sell and which shares are the most tax-optimal to offload.
How can I find the value of my Ro stock?
The value of private stock isn't publicly listed, but it can be estimated based on the company's latest 409A valuation and secondary market data. Platforms like Prospect use predictive models to help you forecast the future value of your shares.
What is Ro's equity worth?
A company's total equity worth is based on its valuation, which fluctuates with funding rounds and overall business performance. To understand what your personal equity stake could be worth, you can use Prospect to model different scenarios and project its potential value.
What is Ro's stock ticker symbol?
As a private company, Ro does not have a stock ticker symbol because its shares are not traded on a public stock exchange. A ticker symbol will be assigned only if and when the company completes an Initial Public Offering (IPO).
Can I buy or sell Ro stock?
Buying stock in a private company like Ro is generally limited to employees exercising options or accredited investors in specific funding rounds. Selling is also restricted, usually to company-approved tender offers or secondary market sales, which platforms like Prospect can help you navigate.
What is the criteria to buy or invest in Ro stock?
Investing in a private company like Ro is typically restricted to employees receiving equity compensation, founders, and accredited investors participating in private funding rounds. Opportunities for the general public to invest are not available until the company goes public.
